Literature DB >> 20207642

Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience.

Federica Mirici-Cappa1, Annagiulia Gramenzi, Valentina Santi, Andrea Zambruni, Antonio Di Micoli, Marta Frigerio, Francesca Maraldi, Maria Anna Di Nolfo, Paolo Del Poggio, Luisa Benvegnù, Gianludovico Rapaccini, Fabio Farinati, Marco Zoli, Franco Borzio, Edoardo Giovanni Giannini, Eugenio Caturelli, Mauro Bernardi, Franco Trevisani.   

Abstract

OBJECTIVES: The number of elderly patients diagnosed with hepatocellular carcinoma (HCC) is expected to increase. We compared the presenting features and outcome of HCC in elderly (>or=70 years) and younger patients (<70 years).
DESIGN: Multicentre retrospective cohort study and nested case-control study. Patients 614 elderly and 1104 younger patients from the ITA.LI.CA database, including 1834 HCC cases consecutively diagnosed from January 1987 to December 2004. Both groups were stratified according to treatment: hepatic resection, percutaneous procedures, transarterial chemoembolisation (TACE). Survival was assessed in the whole population and in each treatment subgroup. Age, sex, aetiology, cirrhosis, comorbidities and cancer stage (CLIP score) were tested as predictors of survival. In each subgroup, differences in patient survival were also assessed after adjustment and matching by propensity score.
RESULTS: Ageing was associated with a higher prevalence of comorbidities, better liver function and CLIP score. Regardless of age, two-thirds of patients underwent radical treatments or TACE. Elderly patients underwent more ablative procedures and fewer resections or TACE sessions. The survival of elderly and younger patients was comparable in each treatment subset, and was predicted by CLIP score. This result was confirmed by the propensity analysis.
CONCLUSIONS: The overall applicability of radical or effective HCC treatments was unaffected by old age. However, treatment distribution differed, elderly individuals being more frequently treated with percutaneous procedures and less frequently with resection or TACE. Survival was unaffected by age and primarily predicted by cancer stage, assessed by the CLIP system, both in the overall population and in treatment subgroups.

Entities:  

Mesh:

Year:  2010        PMID: 20207642     DOI: 10.1136/gut.2009.194217

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  55 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Recent trends in hepatectomy for elderly patients with hepatocellular carcinoma.

Authors:  Masaki Ueno; Shinya Hayami; Masaji Tani; Manabu Kawai; Seiko Hirono; Hiroki Yamaue
Journal:  Surg Today       Date:  2013-10-05       Impact factor: 2.549

3.  Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma.

Authors:  Andreas Andreou; Safak Gül; Andreas Pascher; Wenzel Schöning; Hussein Al-Abadi; Marcus Bahra; Fritz Klein; Timm Denecke; Benjamin Strücker; Gero Puhl; Johann Pratschke; Daniel Seehofer
Journal:  HPB (Oxford)       Date:  2014-09-28       Impact factor: 3.647

Review 4.  Management of hepatocellular carcinoma in the elderly.

Authors:  Mauro Borzio; Elena Dionigi; Giancarlo Parisi; Ivana Raguzzi; Rodolfo Sacco
Journal:  World J Hepatol       Date:  2015-06-18

Review 5.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

Review 6.  Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.

Authors:  Emmanuel A Tsochatzis; Evangelia Fatourou; James O'Beirne; Tim Meyer; Andrew K Burroughs
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

7.  Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals.

Authors:  Felix Krenzien; Moritz Schmelzle; Benjamin Struecker; Nathanael Raschzok; Christian Benzing; Maximilian Jara; Marcus Bahra; Robert Öllinger; Igor M Sauer; Andreas Pascher; Johann Pratschke; Andreas Andreou
Journal:  J Gastrointest Surg       Date:  2018-01-23       Impact factor: 3.452

8.  Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.

Authors:  Ji Eun Lee; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Young Kyoung You; Myung Ah Lee
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 9.  Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review.

Authors:  Annie K Hung; Jennifer Guy
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma.

Authors:  Matan J Cohen; Allan I Bloom; Orly Barak; Alexander Klimov; Tova Nesher; Daniel Shouval; Izhar Levi; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.